Speaking to a group of investors following the July 2008 International Conference on Alzheimer’s Disease (ICAD), Lon Schneider, MD, of the Keck School of Medicine at the University of Southern California compared the current odds of success in late-stage Alzheimer’s Disease drug development to a Major League baseball player at the plate: he is unlikely to get a hit but that doesn’t mean he won’t get one.
The recent Phase III clinical trials in AD have been strikeouts: tarenflurbil (Flurizan), from Myriad Genetics Inc., failed in...